ROIVANT SCIENCES LTD. Net Income (Loss) Available to Common Stockholders, Diluted
ROIVANT SCIENCES LTD. (ROIV) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$376.26 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-05-20
- ROIVANT SCIENCES LTD. net income (loss) available to common stockholders, diluted for fiscal 2026 was -$376.26M.
- ROIVANT SCIENCES LTD. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$171.98M, a 103.95% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. net income (loss) available to common stockholders, diluted for fiscal 2024 was $4.35B.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|
| 2026-03-31 | -$376.26M 10-K · filed 2026-05-20 |
| 2025-03-31 | -$171.98M 10-K · filed 2026-05-20 |
| 2024-03-31 | $4.35B 10-K · filed 2026-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |